vs
BICYCLE THERAPEUTICS PLC（BCYC）与REGIS CORP（RGS）财务数据对比。点击上方公司名可切换其他公司
REGIS CORP的季度营收约是BICYCLE THERAPEUTICS PLC的1.2倍（$57.1M vs $48.0M），REGIS CORP净利率更高（0.8% vs -42.0%，领先42.8%），BICYCLE THERAPEUTICS PLC同比增速更快（1193.3% vs 22.3%），REGIS CORP自由现金流更多（$891.0K vs $-19.9M），过去两年BICYCLE THERAPEUTICS PLC的营收复合增速更高（56.7% vs 7.8%）
Bicycle Therapeutics是一家临床阶段生物制药企业，专注于开发双环肽类创新疗法以解决未被满足的医疗需求，核心管线覆盖肿瘤、罕见病与免疫疾病领域，在欧美布局运营，与全球头部药企达成战略合作推进候选药物落地。
瑞吉斯公司是一家美国美发沙龙运营商，总部位于明尼苏达州明尼阿波利斯市。截至2021年8月，该集团旗下拥有5563家加盟沙龙以及276家直营门店，是北美地区规模领先的美发沙龙连锁经营企业。
BCYC vs RGS — 直观对比
营收规模更大
RGS
是对方的1.2倍
$48.0M
营收增速更快
BCYC
高出1171.0%
22.3%
净利率更高
RGS
高出42.8%
-42.0%
自由现金流更多
RGS
多$20.8M
$-19.9M
两年增速更快
BCYC
近两年复合增速
7.8%
损益表 — Q4 FY2025 vs Q2 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $48.0M | $57.1M |
| 净利润 | $-20.2M | $456.0K |
| 毛利率 | — | — |
| 营业利润率 | -51.5% | 10.8% |
| 净利率 | -42.0% | 0.8% |
| 营收同比 | 1193.3% | 22.3% |
| 净利润同比 | 61.1% | -94.0% |
| 每股收益（稀释后） | $-0.29 | $0.16 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收BCYCRGS
| Q4 25 | $48.0M | $57.1M | ||
| Q3 25 | $11.7M | $59.0M | ||
| Q2 25 | $2.9M | $60.4M | ||
| Q1 25 | $10.0M | $57.0M | ||
| Q4 24 | $3.7M | $46.7M | ||
| Q3 24 | $2.7M | $46.1M | ||
| Q2 24 | $9.4M | $49.4M | ||
| Q1 24 | $19.5M | $49.2M |
净利润BCYCRGS
| Q4 25 | $-20.2M | $456.0K | ||
| Q3 25 | $-59.1M | $1.4M | ||
| Q2 25 | $-79.0M | $116.5M | ||
| Q1 25 | $-60.8M | $250.0K | ||
| Q4 24 | — | $7.6M | ||
| Q3 24 | $-50.8M | $-853.0K | ||
| Q2 24 | $-39.8M | $91.2M | ||
| Q1 24 | $-26.6M | $-2.3M |
营业利润率BCYCRGS
| Q4 25 | -51.5% | 10.8% | ||
| Q3 25 | -558.6% | 10.0% | ||
| Q2 25 | -2965.8% | 12.1% | ||
| Q1 25 | -703.7% | 8.8% | ||
| Q4 24 | — | 11.8% | ||
| Q3 24 | -2385.9% | 4.6% | ||
| Q2 24 | -498.3% | — | ||
| Q1 24 | -162.4% | 8.3% |
净利率BCYCRGS
| Q4 25 | -42.0% | 0.8% | ||
| Q3 25 | -503.7% | 2.3% | ||
| Q2 25 | -2703.8% | 192.9% | ||
| Q1 25 | -608.9% | 0.4% | ||
| Q4 24 | — | 16.4% | ||
| Q3 24 | -1898.4% | -1.9% | ||
| Q2 24 | -425.3% | 184.7% | ||
| Q1 24 | -136.0% | -4.7% |
每股收益（稀释后）BCYCRGS
| Q4 25 | $-0.29 | $0.16 | ||
| Q3 25 | $-0.85 | $0.49 | ||
| Q2 25 | $-1.14 | $43.67 | ||
| Q1 25 | $-0.88 | $0.08 | ||
| Q4 24 | — | $2.71 | ||
| Q3 24 | $-0.74 | $-0.36 | ||
| Q2 24 | $-0.77 | $38.40 | ||
| Q1 24 | $-0.62 | $-1.00 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $628.1M | $18.4M |
| 总债务越低越好 | — | $113.3M |
| 股东权益账面价值 | $610.0M | $188.7M |
| 总资产 | $717.6M | $588.3M |
| 负债/权益比越低杠杆越低 | — | 0.60× |
8季度趋势，按日历期对齐
现金及短期投资BCYCRGS
| Q4 25 | $628.1M | $18.4M | ||
| Q3 25 | $648.3M | $16.6M | ||
| Q2 25 | $721.5M | $17.0M | ||
| Q1 25 | $793.0M | $13.3M | ||
| Q4 24 | $879.5M | $10.2M | ||
| Q3 24 | $890.9M | $6.3M | ||
| Q2 24 | $961.4M | $10.1M | ||
| Q1 24 | $457.0M | $5.9M |
总债务BCYCRGS
| Q4 25 | — | $113.3M | ||
| Q3 25 | — | $111.3M | ||
| Q2 25 | — | $110.8M | ||
| Q1 25 | — | $112.0M | ||
| Q4 24 | — | $111.5M | ||
| Q3 24 | — | $95.2M | ||
| Q2 24 | $30.9M | $99.5M | ||
| Q1 24 | $30.8M | $179.7M |
股东权益BCYCRGS
| Q4 25 | $610.0M | $188.7M | ||
| Q3 25 | $618.5M | $187.6M | ||
| Q2 25 | $668.9M | $185.6M | ||
| Q1 25 | $740.3M | $68.6M | ||
| Q4 24 | $793.1M | $66.7M | ||
| Q3 24 | $831.0M | $56.4M | ||
| Q2 24 | $873.8M | $56.8M | ||
| Q1 24 | $356.0M | $-35.8M |
总资产BCYCRGS
| Q4 25 | $717.6M | $588.3M | ||
| Q3 25 | $764.0M | $592.1M | ||
| Q2 25 | $832.2M | $599.0M | ||
| Q1 25 | $883.9M | $511.2M | ||
| Q4 24 | $956.9M | $530.1M | ||
| Q3 24 | $996.7M | $508.9M | ||
| Q2 24 | $1.1B | $530.5M | ||
| Q1 24 | $547.1M | $543.7M |
负债/权益比BCYCRGS
| Q4 25 | — | 0.60× | ||
| Q3 25 | — | 0.59× | ||
| Q2 25 | — | 0.60× | ||
| Q1 25 | — | 1.63× | ||
| Q4 24 | — | 1.67× | ||
| Q3 24 | — | 1.69× | ||
| Q2 24 | 0.04× | 1.75× | ||
| Q1 24 | 0.09× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-19.3M | $1.7M |
| 自由现金流经营现金流 - 资本支出 | $-19.9M | $891.0K |
| 自由现金流率自由现金流/营收 | -41.5% | 1.6% |
| 资本支出强度资本支出/营收 | 1.2% | 1.4% |
| 现金转化率经营现金流/净利润 | — | 3.65× |
| 过去12个月自由现金流最近4个季度 | $-252.0M | $14.9M |
8季度趋势，按日历期对齐
经营现金流BCYCRGS
| Q4 25 | $-19.3M | $1.7M | ||
| Q3 25 | $-71.2M | $2.3M | ||
| Q2 25 | $-72.8M | $6.8M | ||
| Q1 25 | $-86.4M | $6.2M | ||
| Q4 24 | $-164.7M | $2.1M | ||
| Q3 24 | $-39.8M | $-1.3M | ||
| Q2 24 | $-44.6M | $5.1M | ||
| Q1 24 | $-70.9M | $-277.0K |
自由现金流BCYCRGS
| Q4 25 | $-19.9M | $891.0K | ||
| Q3 25 | $-71.8M | $1.9M | ||
| Q2 25 | $-73.3M | $6.2M | ||
| Q1 25 | $-87.0M | $5.9M | ||
| Q4 24 | $-166.0M | $1.7M | ||
| Q3 24 | $-40.3M | $-1.4M | ||
| Q2 24 | $-45.0M | $5.1M | ||
| Q1 24 | $-70.9M | $-326.0K |
自由现金流率BCYCRGS
| Q4 25 | -41.5% | 1.6% | ||
| Q3 25 | -612.3% | 3.2% | ||
| Q2 25 | -2509.7% | 10.3% | ||
| Q1 25 | -871.7% | 10.3% | ||
| Q4 24 | -4475.7% | 3.6% | ||
| Q3 24 | -1504.7% | -3.0% | ||
| Q2 24 | -481.2% | 10.3% | ||
| Q1 24 | -362.9% | -0.7% |
资本支出强度BCYCRGS
| Q4 25 | 1.2% | 1.4% | ||
| Q3 25 | 5.7% | 0.7% | ||
| Q2 25 | 17.1% | 0.9% | ||
| Q1 25 | 6.1% | 0.6% | ||
| Q4 24 | 33.3% | 0.9% | ||
| Q3 24 | 16.3% | 0.0% | ||
| Q2 24 | 4.5% | 0.0% | ||
| Q1 24 | 0.1% | 0.1% |
现金转化率BCYCRGS
| Q4 25 | — | 3.65× | ||
| Q3 25 | — | 1.68× | ||
| Q2 25 | — | 0.06× | ||
| Q1 25 | — | 24.80× | ||
| Q4 24 | — | 0.28× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | 0.06× | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
BCYC
暂无分部数据
RGS
| Franchise Segment | $37.9M | 66% |
| Royalty | $13.6M | 24% |
| Other | $2.8M | 5% |
| Fees | $1.8M | 3% |
| Franchise Fees | $1.0M | 2% |
